Alzheimer's Therapeutics Reviewed by NeuroInvestment

CARDIFF, CA, Sep 02 (MARKET WIRE) --
NI Research today released the September issue of NeuroInvestment,
featuring a review of Alzheimer's therapeutics. This review stands in
sharp contrast with the common rehashing of press releases and corporate
spin. The implications of recent clinical failures are discussed in terms
of how they affect the primacy of the amyloidmodel. The review also
discusses a challenge to the validity of the BACE target of concern to
the many companies that have devoted resources to BACE inhibitors.

These developments require a recalibration of what constitutes a
comprehensive AD pipeline, and opens the door for therapeutics utilizing
other mechanisms of action, including those addressing tau, metal-binding,
and neurotrophics.

Over 170 therapeutics programs from 110 companies are included in this
review. They range from highly publicized projects like Elan/Wyeth's
bapineuzumab, Lilly's amyloid antibody, Medivation'sDimebon, and Prana's
PBT-2; to those whose star is now ascending, such as Allon Therapeutics
and TauRx; to the still under-the-radar programs from such companies as
Accera, American Life Sciences Partners, EnVivo Pharmaceuticals,
Neuronascent, and Sanomune.

The September review examines the increased disregard for thorough Phase
II testing in Alzheimer's, the seeds being sown for catastrophic Phase III
failures like those already experienced by Myriad Genetics and Neurochem.
It also includes a review of Allon Therapeutics (TSX: NPC); a look at
Vanda's fading prospects; positive data for Titan Pharmaceuticals and
Cortex Pharmaceuticals (AMEX: COR); and a comment on Catalyst Pharma's
plan to develop vigabatrin for obesity.

NeuroInvestment is the independent, monthly review of the
neurotherapeutics area. Its reputation has been built via thirteen years
of objective, insightful, and critical coverage of the neurotherapeutics
field. A one-year corporate subscription is $1600, email or hardcopy. Add
$250 for dual delivery, add $50 for airmail delivery outside North
America. A three month trial is US$600. The September issue is also being
made available as a single purchase, US$400.

NI Research is the leading publisher of independent research on the
neurotherapeutics industry. NI Research has published NeuroInvestment
since 1995, the Private CNS Company Review since 2003, and CNS
Disorders/Therapeutics since 2007. NI Research also provides inlicensing
consultation and custom services. NI Research has developed an unmatched
information base regarding both publicly and privately-held neuro-oriented
companies.

Contact:
NI Research
P.O. Box 1028, Cardiff CA 92007
760.230.2581
Email Contact
Website: www.niresearch.com

Copyright 2008, Market Wire, All rights reserved.

-0-